MS HB1760

Creates the Mississippi Opioid Response Center of Excellence (MSORCE) to be administered by the Mississippi Public Health Institute, providing technical assistance and evaluation services for opioid settlement grantees

Establishes the Opioid Settlement Fund in the State Treasury to receive settlement monies from opioid litigation with distributors (Cardinal Health, McKesson, AmerisourceBergen), manufacturers (Purdue Pharma, Janssen/Johnson & Johnson, Allergan, Teva), and pharmacy chains (CVS, Walgreens, Walmart, Kroger)

Creates a 15-member voting Mississippi Opioid Settlement Fund Advisory Council, chaired by the Attorney General, to review grant applications and make funding recommendations to the Legislature

Limits nonabatement expenditures to no more than 30% of settlement funds, with the Attorney General having oversight authority to ensure compliance with settlement terms

Requires the council to submit annual reports by December 1 summarizing fund distribution and program outcomes, with reports published on the Attorney General's website; effective date is July 1, 2026